We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current CTNM market cap is 363.21M. The company's latest EPS is USD 0.8814 and P/E is 15.99.
Quarter End | Mar 2024 | Jun 2024 |
---|---|---|
USD (US$) | ||
Total Revenue | 0 | 0 |
Operating Income | -9.93M | -10.94M |
Net Income | -8.42M | -9.01M |
Year End 31 December 2023 | 2023 |
---|---|
USD (US$) | |
Total Revenue | 50M |
Operating Income | 16.08M |
Net Income | 22.72M |
Quarter End | Mar 2024 | Jun 2024 |
---|---|---|
USD (US$) | ||
Total Assets | 123.56M | 221.36M |
Total Liabilities | 6.57M | 3.85M |
Total Equity | -75.63M | 217.5M |
Year End 31 December 2023 | 2023 |
---|---|
USD (US$) | |
Total Assets | 130.39M |
Total Liabilities | 5.7M |
Total Equity | -67.94M |
Market Cap | 363.21M |
Price to Earnings Ratio | 15.99 |
Price to Sales Ratio | 7.26 |
Price to Cash Ratio | 23.39 |
Price to Book Ratio | 2.91 |
Dividend Yield | - |
Shares Outstanding | 25.78M |
Average Volume (1 week) | 74.81k |
Average Volume (1 Month) | 76.82k |
52 Week Change | -2.83% |
52 Week High | 22.00 |
52 Week Low | 12.33 |
Spread (Intraday) | 2.18 (13.4%) |
Company Name | Contineum Therapeutics Inc |
Address |
1209 orange street wilmington, delaware 19801 |
Website | https://www.contineum-tx.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions